The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.00
Bid: 18.50
Ask: 19.50
Change: -0.25 (-1.30%)
Spread: 1.00 (5.405%)
Open: 19.25
High: 19.25
Low: 19.00
Prev. Close: 19.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Parsortix Regulatory Approval Update

7 May 2013 07:00

RNS Number : 0281E
Angle PLC
07 May 2013
 



For immediate release

 

7 May 2013

 

ANGLE plc

("ANGLE" or "the Company")

 

PARSORTIX REGULATORY APPROVAL UPDATE

 

 

ANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce the appointment of a specialist regulatory company, Medical Device Management (MDM), to manage the process of obtaining regulatory authorisations for the clinical use of the Parsortix cell separation system.

 

MDM is focused entirely on the medical devices sector and has expertise worldwide in quality assurance systems, regulatory submissions and compliance. Its clients range from small innovative companies to international medical devices businesses.

 

In the European Union (EU), marketing authorisation will be via a CE Mark, which will give approval for clinical sales throughout the EU. In the US, the process requires the submission of a 510(k) application to the FDA. Authorisation under 510(k) will allow the Company to make the product available throughout the US for use in treating patients.

 

MDM's initial analysis has confirmed ANGLE's expectation of securing regulatory authorisation in the EU by the end of the current calendar year and making a regulatory submission to the FDA in the US in early 2014.

 

Although ANGLE has not yet started to market Parsortix, there has been a stream of potential users expressing interest in the product, particularly in its harvesting capability. These include major hospitals, leading research groups and several commercial companies. Geographically, interest has come from across the UK as well as several international locations including the US, Canada and Australia.

 

 

ANGLE's Founder and Chief Executive, Andrew Newland, commented:

"We are very pleased to have put in place a plan for securing regulatory authorisations in Europe and the United States. MDM are experts in this field and it is reassuring that they have expressed confidence in our ability to secure the authorisations needed to enter the multi-billion dollar market for the clinical use of our cell separating technology."

 

 

 

 

For further information:

 

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Cenkos Securities

Stephen Keys, Adrian Hargrave (Nominated adviser)

Andy Roberts, Christian Hobart (Sales)

 

020 7397 8900

Buchanan

Mark Court, Fiona Henson, Sophie Cowles

020 7466 5000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEXLFBXEFLBBD
Date   Source Headline
26th Jan 20127:00 amRNSInterim Results
26th Jan 20127:00 amRNSNovocellus Update
26th Jan 20127:00 amRNSFundraising
23rd Jan 20127:01 amRNSParsortix Update
19th Jan 20127:00 amRNSNotice of Interim Results and Webcast
16th Dec 20117:00 amRNSParsortix Update - Validation for Lung Cancer
7th Dec 20117:00 amRNSParsortix Update
21st Nov 20117:00 amRNSShare Options
16th Nov 20117:00 amRNSNovocellus Update
15th Nov 20117:00 amRNSIssue of equity and Total Voting Rights
11th Nov 20117:00 amRNSValidation for Prostate Cancer
10th Nov 20117:00 amRNSChange of Adviser
7th Nov 20113:53 pmRNSACOLYTE BIOMEDICA COURT JUDGEMENT
31st Oct 20117:00 amRNSWORLD TECHNOLOGY NETWORK AWARD
27th Oct 20119:26 amRNSDirector's share transfer
24th Oct 20117:00 amRNSPortfolio Company Announces Strengthening Sales
12th Oct 20117:00 amRNSIssue of equity and Total Voting Rights
6th Oct 20112:33 pmRNSResults of 2011 Annual General Meeting
6th Oct 20117:00 amRNS2011 AGM Statement
5th Oct 20117:00 amRNSParsortix Update and Issue of Equity
4th Oct 20117:00 amRNSWEB CAST - Parsortix Update
28th Sep 20117:00 amRNSParsortix Update
15th Sep 20113:20 pmRNSHolding(s) in Company
14th Sep 20119:16 amRNSAnnual Report and Accounts and Notice of AGM
13th Sep 20113:54 pmRNSHolding(s) in Company
12th Sep 20112:53 pmRNSHolding(s) in Company
8th Sep 20115:26 pmRNSHolding(s) in Company
31st Aug 20112:44 pmRNSShare Options
26th Aug 20114:26 pmRNSHolding in Company
17th Aug 20117:00 amRNSIssue of equity and Total Voting Rights
28th Jul 20117:00 amRNSPreliminary Results
25th Jul 20117:00 amRNSGeomerics Announces Agreement with Epic Games
15th Jul 20117:00 amRNSConditional Fundraising
28th Jun 20117:00 amRNSParsortix Update
18th May 20117:00 amRNSAcolyte Biomedica Update
5th May 20117:00 amRNSParsortix Update
28th Apr 20117:00 amRNSGeomerics Corporate Deal Further Progress
14th Apr 20117:00 amRNSGeomerics progress
2nd Mar 20114:54 pmRNSDirector/PDMR Shareholding
1st Mar 20117:00 amRNSGeomerics Real-Status deal
27th Jan 20117:00 amRNSInterim Results
25th Jan 20119:00 amRNSNotice of Interim Results
12th Jan 20117:00 amRNSGeometrics Corporate Deal Update
7th Jan 20117:00 amRNSNeuroTargets Patent Grant
6th Dec 201011:38 amRNSHolding(s) in Company
17th Nov 201010:16 amRNSHolding(s) in Company
13th Oct 201010:06 amRNSDirector/PDMR Shareholding
13th Oct 201010:01 amRNSHolding(s) in Company
11th Oct 20101:34 pmRNSAcolyte Biomedica update
8th Oct 20107:00 amRNSPlacing Update and TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.